Warning: members of the public are being contacted by people claiming to work for AXA Investment Managers UK Limited.  Find out more information and what to do by clicking here.

Robotech strategy - September 2022

  • 02 November 2022 (3 min read)

We saw some relative strength in some of our Healthcare names

  • Most major markets ended September month below the prior lows seen in June
  • Softness seen in a number of areas 
  • We added a position in Mitsubishi Electric, a large Japanese industrial automation business 

What’s happening?

Equity markets fell sharply in September, with most major markets ending the month below the prior lows seen in June.   Macro-economic impacts continue to dominate, with concerns around rising energy prices and broader inflation dampening consumer confidence.  During September, the Federal Reserve hiked interest rates by 0.75%1 , for the 3rd consecutive time following similar increase in June and July.

Despite the economic challenges at present, labour markets continue to be tight and job vacancies are high.  Whilst it is possible that we will see some softness develop here alongside a weaking economy, we continue to believe that these dynamics should support automation demand – where businesses can’t find adequate labour, or labour becomes increasingly expensive – these are areas where automation can help reduce some of these issues.

In light of the challenging economic environment, earnings estimates for the remainder of 2022 and in to 2023 are coming down.  Within the coming weeks, we will hear directly from companies as they report their calendar Q3 earnings and provide forecasts for Q4.

Portfolio positioning and performance

September was a challenging month for performance with softness seen in a number of areas.  We saw weakness in several of our automated logistics names, with Kion, a German company focused on warehouse automation solutions, announcing that profitability would be impacted by an inability to pass through rising input cost to customers and some customer cancellations of planned deployments.

Elsewhere semiconductor names were again broadly weaker, impacted by concerns of a slowing global economy and concerns around US export restrictions to China being implemented on certain chips and related technologies that can be used for Artificial Intelligence applications.

We saw some relative strength in some of our Healthcare names, such as Dexcom (US manufacturer of automated blood sugar level monitoring devices for diabetic patients), Axonics (US Sacral Neuromodulation company) and Global Medical (US spinal surgery company developing a surgical robot).  In General, Medtech companies are seen as being less economically sensitive and as such the share prices have been more resilient during bouts of volatility.

During the month we added a position in Mitsubishi Electric, a Japanese Industrial company with a large Industrial Automation business.  Valuations appear attractive, with the company trading at a Price to Book ratio cheaper than during height of the US/China trade war in 2018 and approaching the levels seen in the Global Financial Crisis.  Additionally, as a Japanese company that sells products globally, the company may see some benefit from the weaker Japanese Yen.

We added to our small position in Tesla during the month.  Whilst we anticipate that near term quarterly production volumes and deliveries may continue to be impacted by supply chain issues and lockdowns in China, we see signs that Tesla are continuing to make progress on its FSD Technology (Full Self Driving) and believe that lower cost manufacturing capacity coming online in Berlin, Shanghai and Austin supports the business growth and margin profile of the business.

During August, Schneider Electric confirmed that they were considering making an offer for AVEVA, a British software company in which they already owned a 60% stake.  During September a bid from Schneider was announced at a roughly 40%2 premium to whether the stock was trading prior to the rumours surfacing.  As a result, we exited our position in AVEVA.


Reported inflation numbers from around the world continue to be high, particularly in Europe where Energy prices continue to drive inflation reports higher.  There is some relief here in Energy Prices as a number of countries have taken notable steps to cap household bills or make efforts to moderate prices.  This will still weigh on consumer spending power, but the worst-case scenarios in terms of consumer bills appear to have been averted, with governments absorbing the impacts instead.

In this difficult macro backdrop, we have seen share prices for some companies fall significantly, such that valuations for medium to longer term investors now appear rather attractive.  However, the earnings outlook for these businesses, at least near term, is more uncertain than it has been in some time.  We continue to believe that the opportunities driven by the long-term themes within the Robotech strategy are robust.  As investors we aim to focus on identifying well managed businesses, with proven operating models and large opportunities ahead of them and believe that this is the right approach to investing in the long-term growth opportunities present within robotics and Automation.

No assurance can be given that the Robotech Strategy will be successful. Investors can lose some or all of their capital invested. The Robotech strategy is subject to risks including; Equity; Emerging markets; Investments in specific sectors or asset classes; Global investments; Investments in small and/or micro capitalisation universe; ESG.

  • U291cmNlOiBGZWRlcmFsIFJlc2VydmUgaXNzdWVzIEZPTUMgc3RhdGVtZW50LCAyMS8wOS8yMDIy
  • U291cmNlJm5ic3A7OiBCbG9vbWJlcmcg4oCTIDIxLzA5LzIwMjI=


Investing in automation and robotics - How are companies capitalising on robotics – and what does this mean for investors?

Find out more

Related Articles


Robotics sector looks primed for further growth in 2024


Taking stock of 2023: Tech Update

  • by AXA Investment Managers
  • 21 December 2023 (5 min read)

Robotech strategy - March 2022


    Not for Retail distribution: This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

    Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs incurred when issuing or redeeming units. The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. Exchange-rate fluctuations may also affect the value of their investment. Due to this and the initial charge that is usually made, an investment is not usually suitable as a short term holding.

    This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities. The strategies discussed in this document may not be available in your jurisdiction.

    Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

    Please note that the management company reserves the right, at any time, to no longer market the product(s) mentioned in this communication in a European Union country by notification to its authority of supervision in accordance with European passport rules. In the event of dissatisfaction with the products or services, you have the right to make a complaint either with the marketer or directly with the management company (more information on our complaints policy available in English here). You also have the right to take legal or extra-judicial action at any time if you reside in one of the countries of the European Union. The European online dispute resolution platform allows you to enter a complaint form (by clicking here) and informs you, depending on your jurisdiction, about your means of redress (by clicking here).

    Issued in the U.K. by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales, No: 01431068. Registered Office: 22 Bishopsgate, London, EC2N 4BQ. In other jurisdictions, this document is issued by AXA Investment Managers SA’s affiliates in those countries.

    Risk Warning

    The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested.